Tobacco heated products: a new challenge in tobacco control
Por:
Peruga, A, Lozano, FR, Lopez, MJ, Garcia, RC, Nerin, I, Sureda, X, Fernandez, E
Publicada:
1 ene 2022
Ahead of Print:
1 ene 2022
Resumen:
As cigarette sales decline, the tobacco industry has turned to the sale of heated tobacco products (HTP), which are on the rise. We are concerned with reports erroneously indicating that heated tobacco is associated with a lower risk of cancer and other diseases than conventional cigarettes, citing as a source the Food and Drug Administration (FDA) of the United States. The FDA has indeed authorized the sale of an HTP, but denies that this approval is an endorsement of the product or that it is safe. Philip Morris asked the FDA to approve this product as a "modified risk" tobacco product. However, the Agency denied that the risk to users' health was less than conventional cigarettes, despite emitting less amount of some toxicants. Spain and the European Union should end the regulatory privileges that HTPs have until now. We identified at least five aspects to improve: 1) compliance with the prohibition of HTPs use where smoking is prohibited; 2) control of the prohibition of advertising, promotion, and sponsorship of HTPs; 3) that HTPs carry the same type of labeling as cigarettes; 4) limit that HTPs have characteristic aromas; and 5) treat HTPs fiscally at the same level as cigarettes. (c) 2021 SESPAS. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Filiaciones:
Peruga, A:
Inst Invest Biomed Bellvitge IDIBELL, Grp Invest Control Tabaco, Lhospitalet De Llobregat, Barcelona, Spain
CIBER Enfermedades Resp CIBERES, Madrid, Spain
Univ Desarrollo, Fac Med, Clin Alemona, Ctr Epidemiol & Polit Salud, Santiago, Chile
Lozano, FR:
European Network Smoking & Tobacco Prevent, Bruselas, Belgium
Lopez, MJ:
Agencia St Publ Barcelona, Barcelona, Spain
CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain
Inst Invest Biomed St Pau, Barcelona, Spain
Garcia, RC:
Ctr Salud Delicias Sur, Zaragoza, Spain
Univ Zaragoza, Fac Med, Zaragoza, Spain
Nerin, I:
Univ Zaragoza, Fac Med, Zaragoza, Spain
Sureda, X:
Inst Invest Biomed Bellvitge IDIBELL, Grp Invest Control Tabaco, Lhospitalet De Llobregat, Barcelona, Spain
CIBER Enfermedades Resp CIBERES, Madrid, Spain
Univ Alcala, Fac Med, Grp Invest Salud Publ & Epidemiol, Madrid, Spain
CUNY, Escuela Salad Publ & Polit Salud, Dept Epidemiol & Bioestadist, Nueva York, NY USA
Fernandez, E:
Inst Invest Biomed Bellvitge IDIBELL, Grp Invest Control Tabaco, Lhospitalet De Llobregat, Barcelona, Spain
CIBER Enfermedades Resp CIBERES, Madrid, Spain
Inst Catala Oncol, Ctr Colaborador OMS Control Tabaco, Unidad Control Tabaco, Lhospitalet De Llobregat, Barcelona, Spain
Univ Barcelona, Fac Med & Ciencias Salud, Campus Bellvitge, Lhospitalet De Llobregat, Barcelona, Spain
gold, Green Published, All Open Access, Gold, Green
|